Long Read Analysis in Spinal Muscular Atrophy - LOREASI

Condition(s) studied

Investigational drug(s) / intervention(s)

blood sample: For subjects who agree to participate in the study, a blood sample will be taken (2x5 mL on EDTA) and sent the same day at 4°C to the genetics laboratory at Rouen University Hospital using a carrier that guarantees delivery on D+1

Study summary

Spinal Muscular Atrophy (SMA) is a severe neuromuscular disease caused by deletion of the SMN1 gene, with the most severe form leading to death in children without treatment. Genetic counselling to detect couples where both partners are carriers is particularly important. In some countries, preconception screening is offered. However, some carriers escape detection due to the existence of two copies of the SMN1 gene side-by-side (2+0 genotype). Currently, no molecular genetic methods used for diagnostic purposes can detect these 2+0 genotypes, which pose a significant challenge in genetic counselling.

This study aims to use new technologies based on the analysis of ultra-long molecules to detect side-by-side duplications of the SMN1 gene to detect heterozygous subjects not identified by current techniques and improve genetic counselling.

Eligibility

Primary outcome measure(s)

• Ability to identify a [2+0] SMN1 genotype — From enrollment until the end of the analyses (36 months)

Trial sites (1)

More University Hospital, Rouen trials in France

Other trials for the same condition